Azercabtagene Zapreleucel

通用CAR-T五大技术路线全景总结:传统UCART(TRAC+B2M双KO)/多编辑协同(Regnase-1 KO等)/碱基与先导编辑(无DSB)/iPSC来源(FT819)/体内CAR-T(SYS6055)——从"双KO"到"多编辑协同"的进化逻辑·各路线编辑靶点/受体导入/优势风险对比 GCT前沿·公司官方/学术披露/顶刊文献·📖 约 9036 字 · 22 分钟·🔗 YTS109(Nature Medicine,2025) 一、引言:通用CAR-T的"基因编辑改造"时代 通用型(异体/现货型)CAR-T是细胞治疗"降本增效"的终极答案:从自体2-4周制造周期→现货随取随用,从单人单批→健康供体批量生产。但代价是必须通过基因编辑改造解决三大免疫难题:GVHD(移植物抗宿主病,供体T细胞攻击宿主)、HvGR(宿主抗移植物排斥,宿主免疫清除异体细胞)、T细胞耗竭(功能持久性)[^2][^3][^4]。2025-2026年,这一赛道迎来关键转折:华夏英泰YTS109(CD19 STAR-T)治疗SLE的数据发表于Nature Medicine,是全球首个通用型STAR-T的已发表临床证据[^1][^2];CRISPR Tx CTX112将Regnase-1 KO策略扩展至自免[^3][^9];Fate FT819(iPSC来源)在SLE无清淋条件下展示临床活性[^7][^8]。 如果你是一名患者或家属:通用CAR-T意味着"等得起"的治疗——不需要采集自身细胞等2-4周,更适合病情快速进展或自身细胞质量差的患者;但需要理解异体细胞可能被排斥、疗效持久性弱于自体[^2][^3]。 如果你是一名临床医生:通用CAR-T的基因编辑改造决定排斥风险与持久性——TCR编辑杜绝GVHD是底线,HLA编辑深度决定HvGR,Regnase-1/iPSC策略决定持久性——掌握这三大维度的权衡是评估患者转介的关键[^2][^3][^7]。 如果你在biotech新药研发:通用CAR-T的"基因编辑改造"是当前CGT最活跃的技术竞技场——从双KO(TRAC+B2M)到多编辑协同(Regnase-1/PD-1等),从慢病毒随机插入到定点整合,从DSB编辑到碱基/先导编辑,从原代T到iPSC——每一层编辑叠加都意味着新的科学假设与工艺挑战[^2][^3][^4]。二、通用CAR-T的三大痛点与编辑策略框架 通用CAR-T的基因编辑改造始终围绕三大痛点展开[^2][^3]:(1)GVHD——TCR编辑:破坏TCRα恒定区(TRAC)使供体T细胞无法识别宿主MHC,是异体T细胞最经典的编辑靶点,覆盖几乎所有通用CAR-T方案;(2)HvGR——HLA编辑:敲除或修饰HLA-I类分子以降低宿主T细胞/NK细胞清除,主流策略为B2M(β2微球蛋白)敲除彻底清除HLA-I,或以部分修饰平衡"抗T排斥"与"抗NK杀伤";(3)耗竭——功能编辑:敲除Regnase-1等负向调控分子或PD-1,提升记忆样T细胞占比、延缓耗竭、增强持久性[^3][^9]。行业框架判断:双KO(TRAC+B2M)是"已验证但受限"的基线,2025-2026年最活跃的迭代方向是多编辑协同——在TRAC+B2M基础上叠加Regnase-1(CTX112)、PD-1(Caribou CB-010)等第三/第四编辑[^3][^4][^9]。 华夏英泰(清华大学林欣教授团队创立)是通用CAR-T领域的重要玩家之一,其YTS109(CD19 STAR-T)治疗难治性SLE的数据于2025年9月发表于Nature Medicine——3例难治性SLE合并狼疮肾炎患者,12个月随访无GvHD/CRS/ICANS,全部达到SRI-4缓解,是全球首个通用型STAR-T的已发表临床证据[^1][^2]。该研究以已发表文献形式公开了产品概念与临床数据,但具体的基因编辑组合细节未在公开文献中披露,本文不展开其编辑工艺[^1][^2]。三、三大基因编辑靶点的生物学逻辑(基于已发表文献) 1. TRAC(TCRα恒定区)KO——通用T细胞的"第一性原则":破坏TCRα链→细胞表面丢失完整TCR-CD3复合体→供体T细胞无法识别宿主MHC,从根源杜绝GVHD。这是异体T细胞最经典的编辑靶点,几乎覆盖所有通用CAR-T方案[^2][^3][^4]。部分新一代方案将CAR/受体"定点敲入"TCR位点,一次编辑同时完成受体导入与GVHD消除——这类"敲入即敲除"设计已见于多家公开技术路线与已发表文献[^2][^3]。 2. B2M/HLA-I编辑——"完全隐身"与"部分隐身"的权衡:常规通用CAR-T敲除B2M(β2微球蛋白)彻底清除HLA-I类分子,完全规避宿主T细胞识别,但代价是MHCI归零→NK细胞通过"丢失自我"机制强烈攻击异体细胞。行业正在探索平衡方案:保留部分HLA-I(如单倍型/单基因座敲除)以抵抗NK杀伤,或敲入HLA-E/HLA-G结合NK抑制性受体"主动隐身"(科济THANK-uCAR公开路线)[^3][^12]。这是"抗NK"与"抗T排斥"之间的精妙平衡,也是与B2M全敲路线最核心的分野[^2][^3][^12]。 3. Regnase1(ZC3H12A)KO——解除T细胞的"天然刹车":Regnase1是胞质核糖核酸酶,降解大量活化/记忆相关mRNA,是T细胞天然负向调控分子。敲除后:(1)上调TCF1→促进耗竭前体T细胞生成→提升记忆样T细胞占比→延缓耗竭;(2)BATF等转录本累积→IFNγ/TNFα/IL-2分泌升高→杀伤增强;(3)线粒体代谢重编程→TME耐受度提升[^3][^9]。重大安全隐患(公开文献共识):Regnase-1功能完全缺失可使T细胞过度活化、有自身炎症倾向——人体先天Regnase-1功能缺失即发生严重自身免疫病——因此工程化设计需控制表达水平/细胞亚群,临床需严密监控CRS[^3][^9]。四、受体导入方式:定点整合与随机整合之争 受体导入是通用CAR-T工艺的"第二战场":(1)慢病毒(LV)随机插入——传统UCART(Cellectis/Allogene/CRISPR Tx)主流方案,效率高但随机整合基因组→插入突变致癌风险,拷贝数不可控[^3][^4];(2)定点敲入(AAV HDR等)——新一代方案选择:以AAV递送带同源臂的受体表达盒,实现单拷贝定点插入(如TRAC位点),不随机整合、无插入突变风险、拷贝数可控,且"敲入即敲除";限制是AAV包装上限~4.7kb(受体大小需控制)、HDR效率依赖细胞激活状态(原代T一般20-50%,残留未敲入细胞需质控扣除)[^3];(3)转座子(非病毒piggyBac)——上海细胞治疗集团/Precision/Poseida等路线,兼顾效率与较低免疫原性,但插入位点仍具一定随机性[^14][^15]。判断:定点敲入是"工程学正确"但"工艺学艰难"的路线——随着HDR效率提升与碱基编辑成熟,定点整合将成为下一代通用CAR-T的重要配置[^2][^3]。五、STAR-T:已发表文献中的"TCR样"受体证据 STAR(Synthetic T cell Receptor and Antigen Receptor,合成T细胞受体抗原受体)是华夏英泰公开文献中的核心受体概念,属于TCR样工程受体:胞外scFv识别抗原(CAR特征),胞内与内源TCR-CD3信号轴整合,使用更接近生理TCR的信号通路[^1][^2]。已发表文献支持的关键特性:(1)信号更接近生理TCR→反复抗原刺激下不易耗竭,实体瘤浸润能力优于传统28ζ/BBζ CAR;(2)临床证据:YTS109(CD19 STAR-T)治疗3例难治性SLE合并狼疮肾炎患者,Nature Medicine 2025.9发表——12个月随访无GvHD/CRS/ICANS,全部达到SRI-4缓解,DORIS缓解标准评估显示深度应答[^1][^2]。提示:STAR-T的"抗耗竭+天然TCR信号"设计在自免场景展示出差异化潜力,但相关编辑工艺细节以公开文献为准[^1][^2]。六、全球策略横向对比:五条技术路线的"基因编辑改造"全景 表1|通用CAR-T基因编辑五大技术路线对比(2026.8) 技术路线 代表平台 基因编辑靶点 受体导入方式 核心优势 核心风险传统UCART Cellectis UCART/Allogene/CRISPR Tx(CTX110) TRAC+B2M KO(±CD52) 慢病毒随机插入CAR 最成熟;完全消除MHCI避免HvGR;临床验证最多[^3][^4] B2M全敲→NK"丢失自我"强烈杀伤;慢病毒随机插入致癌风险;持久性差[^3][^4]Regnase-1 KO CRISPR Tx CTX112 TRAC+B2M+Regnase-1 KO 慢病毒/AAV(CD19 CAR) 抗耗竭编辑增益;CTX112已扩展SLE/硬皮病[^3][^9] 过度活化/CRS风险;仍需B2M KO的NK问题[^3]碱基/先导编辑 Beam/多家 B2M+Regnase-1(无DSB) AAV HDR敲入CAR无DSB→染色体异常风险低 ;编辑精度高[^3] 碱基编辑器脱靶RNA风险;编辑窗口限制[^3]iPSC来源 Fate FT819 iPSC层面编辑(CD19 CAR+TCR敲除) iPSC分化T细胞(种子库)无限种子库 ;每批一致性高;FT819 SLE无清淋活性[^7][^8] iPSC分化T功能局限;成本/工艺复杂;长期致瘤性待验证[^3][^8]体内CAR-T 石药SYS6055 体内直接编辑T细胞 注射LNP等体内递送 适应症:复发/难治性侵袭性B细胞淋巴瘤;完全颠覆制造范式,周期2-4周→数天[^10] 编辑效率/脱靶/安全性验证初启[^10] 图1|全球通用CAR-T基因编辑技术路线分布(估算) · 查看原文 路线判断:(1)传统双KO(TRAC+B2M)是"已验证但受限"的基线——B2M全敲的NK杀伤与持久性差是行业公认瓶颈,Allogene/Cellectis正承受"核冬天"数据压力[^4][^5][^6];(2)多编辑协同(Regnase-1/PD-1等)是2025-2026最活跃的迭代方向——CTX112(Regnase-1 KO)与Caribou CB-010(PD-1 KO)分别从"抗耗竭"与"抗抑制"方向补全双KO短板[^3][^4][^9];(3)碱基/先导编辑是"下一代安全基线"——无DSB→染色体易位风险趋零,但临床验证仍缺[^3];(4)iPSC来源是"规模化终局"候选——FT819在SLE/硬皮病临床活性证明可行性,但分化T细胞功能局限与成本待解[^7][^8];(5)体内CAR-T是"范式颠覆者"——石药SYS6055 IND(2026.1)打开中国先河,但距临床验证尚远[^10]。七、全球主要玩家管线全景 表2|全球通用CAR-T主要玩家管线进展(2026.8) 公司/平台 产品 编辑策略 适应症 最新进展华夏英泰 (林欣教授团队) YTS109(CD19 STAR-T) 通用型STAR-T平台(编辑细节未公开披露)SLE狼疮肾炎Nature Medicine 2025.9发表 :3例难治性SLE患者,12个月随访无GvHD/CRS/ICANS,均达SRI-4缓解——全球首个通用型STAR-T治疗SLE的已发表证据[^1][^2]Allogene ALLO-501A(CD19) TALEN TRAC KO+CMPK/CD52修饰 B细胞淋巴瘤 STAT 2026.4:清除残留癌细胞优于标准治疗3倍;2026定义为"项目决胜年"[^5][^6]CRISPR Tx CTX110/CTX112 CRISPR TRAC+B2M KO;CTX112加Regnase-1 KO B-NHL→扩展SLE/硬皮病 CTX112自免扩展推进[^3][^9]Fate FT819(CD19)iPSC来源 +CAR敲入+TCR敲除 SLE/系统性硬化症 SLE无清淋或低强度清淋即见临床活性;硬皮病首个临床活性[^7][^8]Cellectis UCART系列 TALEN TRAC+B2M KO B-ALL/AML/T-ALL 通用CAR-T"old guard"之一,数据压力大[^4]Caribou CB-010(CD19) CRISPR TRAC+B2M+PD-1 KO B-NHL 首个PD-1敲除异体CAR-T;Ph1数据观察中[^4]邦耀生物 BRL-303/UCAR-T 通用CAR-T(自免全球首个) 自身免疫病 TyU19等通用CAR-T自免推进[^11]石药集团 SYS6055体内CAR-T 复发/难治性侵袭性B细胞淋巴瘤 2026.1 NMPA IND:中国首个获批临床的体内CAR-T(受理号CXSL2500947)[^10]科济药业 THANK-uCAR平台 通用CAR-T(公开技术路线) B细胞肿瘤(通用) 通用化策略布局,公开资料有限[^12]亘喜生物 (AZ收购) TruUCAR/GC502 双靶点(BCMA/CD19)+TruUCAR通用平台 多发性骨髓瘤/自免 FasTCAR快速生产+TruUCAR通用双引擎;AZ $12亿收购(2023.12)[^13]上海细胞治疗集团 白泽T平台非病毒piggyBac +PD-1纳米抗体自分泌 实体瘤(通用化探索) 非病毒转座子降低制造成本;中国实体瘤CAR-T先锋[^14]Precision BioSciences PBCAR0191 ARCUS核酸酶(TRAC KO) B-NHL ARCUS是尺寸最小的基因编辑核酸酶之一;Ph1数据读出[^15]Poseida (Roche收购) P-BCMA-ALLO1piggyBac转座子 +TALEN(双KO) 多发性骨髓瘤 piggyBac多拷贝CAR整合+TALEN异体编辑;Roche $10亿收购(2025.7)[^15]Wugen WU-NK-101记忆样NK细胞 (非基因编辑现货) AML(现货NK) 记忆样NK:无需基因编辑的现货细胞路线;FDA孤儿药资格[^14]IN8bio INB-100γδ T细胞 (非编辑异体) AML(移植后) γδ T天然MHC非依赖杀伤;无需TCR编辑即无GVHD[^14]Imviva Bio CTA313 双靶(CD19/BCMA)异体CAR-T B细胞介导自免FDA IND批准(2026) :Ph1b篮式设计,多自免适应症[^17]启函生物 (Qihan) QT-019B/QT-019C多基因编辑(6-7基因) 通用型双靶点CAR-T 自免/血液瘤 QT-019B:中国首个自免通用CAR-T获FDA IND+RMAT+BTD;QT-019C编辑7基因,监管批准临床最复杂基因编辑产品之一[^19]北恒生物 (Bioheng) CTA313等 ANSWER®平台通用型CAR-T(CD19/BCMA双靶) 难治性活动性自免FDA IND批准(2026.6) ;另有CTD402(CD7)/RD06-05(BCMA/C D19)[^20]湾岛生物 (Wondercel) 标准化量产CAR-T 通用化/标准化量产平台 血液瘤/实体瘤 传奇生物创始人范晓虎创立;2026.7完成1.4亿元A轮;单批次产量目标3000剂[^21] 竞争格局分层:(1)血液瘤"old guard"承压——Cellectis/Allogene/Caribou/Poseida被Fierce Biotech称为通用CAR-T"old guard",面临自体CAR-T疗效基准与"核冬天"融资环境双重压力[^4];Allogene把2026定义为"项目决胜年",ALLO-501A清除残留癌细胞优于标准治疗3倍的数据是其关键证据[^5][^6];(2)自免成为"第二战场"——华夏英泰YTS109(Nature Medicine已发表)[^1][^2]、CTX112[^9]、FT819[^7][^8]不约而同切入SLE/硬皮病——自免对通用CAR-T的"现货、低清淋、低剂量"需求比血液瘤更匹配;(3)中国力量从"跟随"到"并跑"——华夏英泰(顶刊已发表数据)[^1][^2]、邦耀BRL-303(通用自免)[^11]、石药体内CAR-T[^10]、启函生物QT-019B(6基因编辑,FDA IND+RMAT+BTD)[^19]、北恒生物CTA313(FDA IND 2026.6)[^20]、湾岛生物(范晓虎,标准化量产)[^21]。八、Regnase-1抗耗竭编辑:通用CAR-T的"新共识" Regnase-1(ZC3H12A)KO正在成为通用CAR-T的"新共识编辑"——CRISPR Tx的CTX112在TRAC+B2M基础上叠加Regnase-1 KO,已从B-NHL扩展至SLE/系统性硬化症,验证了"抗耗竭编辑"是通用CAR-T持久性瓶颈的共识解[^3][^9]。Regnase-1敲除通过上调TCF1促进记忆样T细胞、延缓耗竭、增强TME耐受度,但过度活化与自身炎症风险要求"精细调控而非完全敲除"的工程化思路[^3][^9]。行业判断:Regnase-1类编辑正在从"单点创新"走向"平台标配",与TRAC/B2M基础编辑叠加形成多编辑协同格局[^3][^9]。九、iPSC来源策略:FT819的"无限种子库"路径 Fate Therapeutics FT819是iPSC来源通用CAR-T的代表:在iPSC层面完成CD19 CAR敲入+TCR敲除(TRAC),再分化扩增为"无限种子库"的现货T细胞产品[^7][^8]。2026年关键数据:(1)SLE——FT819在无清淋或低强度清淋(苯达莫司汀)条件下即展示临床活性,证明iPSC-CAR-T可降低预处理强度[^7];(2)系统性硬化症——首个临床活性信号[^8]。优势:iPSC每批一致性高、可无限扩增、无供体异质性;短板:iPSC分化T细胞的功能成熟度与体内持久性仍有争议,工艺成本与长期致瘤性需验证[^3][^7][^8]。十、CMC与工艺质控:通用CAR-T的"放行科学" 通用CAR-T的CMC比自体CAR-T复杂一个数量级——基因编辑产品的放行质控是产品安全的核心[^2][^3]。(1)各基因敲除效率:TRAC/B2M/Regnase-1等indel效率+蛋白表型(TCR⁻/HLA⁻)流式确认;(2)受体导入验证:ddPCR/NGS确认拷贝数与插入位点,排除随机插入;(3)基因组安全:染色体易位检测、核型分析、全基因组脱靶测序——多DSB编辑的染色体易位风险是放行焦点[^3];(4)功能质控:体外杀伤、细胞因子谱、记忆/耗竭表型(TCF1/PD-1/TIM-3);(5)残留质控:Cas9残留、AAV载体残留。行业趋势:FDA PreCheck试点推进"工艺可比性"与AI放行监管,通用CAR-T的自动化封闭生产正在将批次间一致性推向新标准[^3]。十一、疗效、安全性与临床数据:代表性路线的"证据对比" 代表性路线的临床证据:(1)华夏英泰YTS109(STAR-T)——Nature Medicine 2025.9发表的全球首个通用型CD19 STAR-T治疗难治性SLE合并狼疮肾炎数据:3例患者12个月随访无GvHD/CRS/ICANS,全部达到SRI-4缓解[^1][^2];(2)Allogene ALLO-501A——B细胞淋巴瘤中清除残留癌细胞(微小残留病)优于标准治疗3倍(STAT News 2026.4),证明通用CAR-T在"清除残留病灶"场景的独特价值[^5][^6];(3)Fate FT819——SLE中无清淋/低强度清淋即见临床活性,降低预处理强度的可行性首次得到验证[^7][^8]。安全性共性挑战:CRS、感染(清淋所致)、异体排斥(输注后宿主免疫恢复期)是通用CAR-T的三类核心AE;Regnase-1类编辑还需额外关注过度活化炎症风险[^2][^3]。十二、投资与市场空间:通用CAR-T的TAM测算 通用CAR-T的市场逻辑:以"现货+低成本"切入自体CAR-T覆盖不了的场景。(1)血液瘤——自体CAR-T已建立的适应症(淋巴瘤/骨髓瘤),通用型以更低价格与即取即用竞争,2030年全球$30-50亿;(2)自身免疫病——CD19 CAR-T在SLE等自免的疗效已被多个已发表研究验证,通用型叠加"现货+低清淋"优势,2030年$20-40亿(华夏英泰YTS109/CTX112/FT819三线并进)[^1][^2][^7][^9];(3)B细胞淋巴瘤/体内CAR-T——石药SYS6055(复发/难治性侵袭性B细胞淋巴瘤)作为体内CAR-T路线代表,2030年$5-10亿(体内CAR-T整体)[^10];合计:2030年全球通用CAR-T峰值销售预计$55-100亿[^3][^9]。投资视角:通用CAR-T的估值锚在"数据里程碑"而非"临床进度"——Allogene 2026年ALLO-501A数据、CTX112自免数据、FT819 SLE数据是2026-2027年三大看点[^4][^5][^6][^7]。十三、风险与挑战:通用CAR-T的"四重门" FDA/EMA监管新进展(2026):(1)2026.6.30 FDA批准全球首个异体调节性T细胞免疫疗法(与HSPC及T细胞联用)——异体细胞疗法监管里程碑,证明"异体细胞产品可获批"路径已打开[^16];(2)FDA新监管框架(2025.12)——肿瘤CAR-T审评要求新药需"优于已批准CAR-T",异体CAR-T注册门槛被抬高[^18];(3)Imviva CTA313获FDA IND(2026)——CD19/BCMA双靶异体CAR-T,Ph1b篮式覆盖多自免适应症[^17];(4)2026顶刊/权威综述共识:通用CAR-T"下一代表面"是编辑策略(Regnase-1/碱基/先导编辑)×递送方式(RNP/mRNA/AAV)×细胞来源(原代T/iPSC)三维优化[^3][^15]。 通用CAR-T要成为主流,需闯过四重门:(1)持久性门——异体细胞被宿主免疫清除,单次输注缓解深度与时长普遍弱于自体,需清淋强化/装甲/重复给药设计[^3][^4];(2)安全性门——多基因编辑的染色体易位、Regnase-1类编辑的过度活化、HLA编辑的免疫逃逸平衡[^2][^3];(3)工艺门——编辑效率、编辑一致性、批次放行的基因组安全质控,通用CAR-T的COGS(单剂综合成本)需压至自体1/3以下才具商业意义[^2][^3];(4)监管门——异体细胞产品的长期存续与致瘤性随访、基因编辑脱靶的终身监测要求,使FDA/EMA审评标准高于自体产品[^3]。核心判断:通用CAR-T的"核冬天"并未结束,但2025-2026年的数据(ALLO-501A/YTS109/FT819)正在打开"春天"的第一道缝[^4][^5][^6][^7]。十四、给各方建议与结语14.1 给患者与家庭 (1)通用CAR-T适合"等不起"的患者——疾病快速进展、自体细胞质量差、或需多次回输;SLE等自免患者可关注YTS109等已发表临床证据支持的通用型试验[^1][^7];(2)理解通用型与自体的差异:即取即用vs持久性更强,与医生讨论清淋预处理强度与再输注可能[^2][^3][^7]。14.2 给临床医生 (1)关注三大自免通用CAR-T临床读出:YTS109(Nature Medicine 2025.9已发表)[^1][^2]、CTX112(CRISPR Tx)[^9]、FT819(Fate)[^7][^8];(2)通用CAR-T的转介评估需关注患者HLA覆盖、既往异体细胞暴露史与清淋耐受性;(3)ALLO-501A的MRD清除数据提示:通用CAR-T在"巩固/清除残留病灶"场景可能优于"末线挽救"[^5][^6]。14.3 给biotech新药研发从业者 (1)编辑策略选择:双KO是基线,多编辑协同是趋势——抗耗竭(Regnase-1)与抗NK(HLA-E敲入/部分HLA保留)是两大迭代方向[^2][^3][^9][^12];(2)导入方式:定点敲入是"工程正确"方向,HDR效率提升与碱基编辑成熟将加速普及[^2][^3];(3)适应症策略:自免是通用CAR-T的"第二战场",SLE/硬皮病对现货与低清淋的需求使通用型比血液瘤更匹配[^1][^2][^7][^9];(4)中国机会:华夏英泰YTS109已跑出Nature Medicine先例,邦耀/石药从不同路线切入——"已发表数据背书+适应症选择"的双重差异化是中国公司的突围路径[^1][^2][^10][^11]。 通用CAR-T的"基因编辑改造"正从"验证时代"走向"分化时代":华夏英泰YTS109(Nature Medicine 2025.9)证明通用型STAR-T在自免的可行性,CTX112证明Regnase-1是行业共识,FT819证明iPSC来源可行,石药SYS6055打开体内路线[^1][^2][^3][^7][^10]。 通用CAR-T的终局不是"替代自体CAR-T",而是"编辑策略(双KO→多编辑协同→无DSB)×细胞来源(原代T→iPSC→体内编辑)×适应症(血液瘤→自免→实体瘤)"的三维矩阵中,与自体/其他疗法按场景共存。谁能率先跑出"持久性+安全性+成本"三角平衡的注册级数据,谁就能在2027-2029年的窗口期定义现货细胞治疗的标准[^2][^3][^4][^5]。 希望加入“全球GCT行业交流群”的读者，请加以下二维码联系工作人员 📚 参考文献溯源 [1]清华大学免疫学研究所官网(2025.9):《Nature Medicine》发表——全球首款通用型CD19 STAR-T(YTS109)治疗难治性SLE合并狼疮肾炎 · 清华大学免疫学研究所(官方) [2]Nature Medicine 2025(Wang D等):Allogeneic CD19-targeted CAR-T therapy in refractory SLE achieved durable remission——YTS109 STAR-T,3例患者12个月随访,无GvHD/CRS/ICANS,SRI-4缓解(NCT05859997) · Nature Medicine(PMID 40446794) · PMID:40446794 [3]PMC 12553175(Su J等,2025):Genome-edited allogeneic CAR-T cells: the next generation——通用CAR-T综述(Regnase-1 KO等) · PMC(综述) [4]Fierce Biotech(2025-2026):Allogeneic CAR-T biotechs fight to escape nuclear winter——Cellectis/Allogene/Caribou/Poseida"old guard" · Fierce Biotech [5]Allogene IR(2026):Positions 2026 as Program-Defining Year——ALLO-501A/ALLO-316数据 · Allogene(官方) [6]STAT News(2026.4):Allogene CAR-T could delay or prevent cancer recurrence——ALLO-501A清除残留癌细胞优于标准治疗3倍 · STAT News [7]Fate IR(2026):FT819 SLE Clinical Activity without Conditioning——无清淋/低强度清淋临床活性 · Fate Therapeutics(官方) [8]CRISPR Medicine News(2026):FT819 shows first clinical activity in systemic sclerosis——iPSC来源CD19 CAR-T硬皮病 · CRISPR Medicine News [9]CRISPR Therapeutics官方IR(2026):CTX112(zugocaptagene geleucel)在SLE/系统性硬化症/炎症性肌炎开展临床研究——自免扩展官方披露 · CRISPR Therapeutics(官方IR) [10]博腾生物官方(2026.1.29):助力石药SYS6055(体内CAR-T)获NMPA临床试验默示许可——受理号CXSL2500947,适应症为复发/难治性侵袭性B细胞淋巴瘤,国内首款获批临床的in vivo CAR-T · 博腾生物(官方) [11]邦耀生物:通用型CAR-T自免管线(BRL-303等)——全球首个自免通用CAR-T(Cell Research发表) · 邦耀生物(公开资料) [12]科济药业:通用CAR-T公开技术路线(THANK-uCAR平台,HLA-E/NKG2A主动隐身策略)——公开资料 · 科济药业(公开资料) [13]亘喜生物(2023.12):AZ $12亿收购——TruUCAR通用平台+GC502(BCMA/CD19双靶)+FasTCAR快速生产(IFLR/多家报道) · IFLR/公开报道 [14]上海细胞治疗集团:白泽T平台——非病毒piggyBac+PD-1纳米抗体自分泌(公司官网公开资料);Wugen WU-NK-101记忆样NK;IN8bio INB-100 γδT(公司公开资料) · 公司官网公开资料(GCT前沿整理) [15]Drug Discovery Trends(2026):50 cell and gene therapy leaders to watch in 2026——Precision ARCUS/Poseida piggyBac(Roche $10亿收购)/Allogene/Fate催化剂 · Drug Discovery Trends [16]FDA官方(2026.6.30):批准首个异体调节性T细胞免疫疗法(与HSPC及T细胞联用)——异体细胞治疗监管里程碑 · FDA(官方) [17]Imviva Bio(2026):CTA313(CD19/BCMA双靶异体CAR-T)获FDA IND批准——Ph1b篮式自免设计 · Imviva Bio(官方) [18]AABB(2025.12):FDA Leaders Outline New Regulatory Framework for Oncologic CAR-T Approvals——新监管框架:需优于已批准CAR-T · AABB News [19]启函生物(Qihan Biotech)官方(2026):QT-019B(多基因编辑通用型双靶点CAR-T)——中国首个自免通用CAR-T获FDA IND+RMAT+BTD;QT-019C编辑7基因 · 启函生物(官方)/BioSpace [20]北恒生物(Bioheng)官方报道(2026):CTA313(ANSWER®平台,CD19/BCMA双靶通用型CAR-T)获FDA IND批准(2026.6)——难治性活动性自免;另有CTD402(CD7)/RD06-05 · 北恒生物(公开报道/药智) [21]湾岛生物(Wondercel,范晓虎创立)公开报道(2026):标准化量产CAR-T平台——2026.7完成1.4亿元A轮融资,单批次产量目标3000剂 · 湾岛生物(公开报道) 细胞基因治疗前沿 每日一篇 CGT 顶刊深度解读 · 数据源自 Nature/Cell/Science/Nat Biotechnol/ASGCT/ESGCT/AACR 内容仅供学术交流，不构成医疗建议

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining - - In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV - - Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial - - Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 - ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); - Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of June 30, 2026, expected to enable data milestones from both PBGENE-HBV and PBGENE-DMD through 2028 - DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “The second quarter marked a defining moment for Precision BioSciences and the hepatitis B field, with the first clinical biopsy evidence that a therapeutic agent can directly target and eliminate cccDNA – data that validate both the science and the development strategy for PBGENE-HBV,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences. “We also continued to advance PBGENE-DMD, with patients now being recruited to participate in the FUNCTION-DMD study. We entered 2026 with a clear plan to deliver multiple important clinical and operational milestones and we are executing against it with near-term data updates from both programs targeted for year end.” Wholly Owned Portfolio: PBGENE-HBV (Hepatitis B Viral Elimination Program) PBGENE-HBV is Precision’s wholly owned in vivo gene editing program being evaluated in ELIMINATE-B, a global clinical trial, as a potential curative treatment for chronic hepatitis B. PBGENE-HBV is the only clinical stage program that targets and eliminates cccDNA, the sole source of viral replication, leading to sustained loss of pgRNA, the precursor for HBV DNA. PBGENE-HBV is the first and only in vivo gene elimination approach to prospectively employ repeat administrations of lipid nanoparticle (LNP) in chronic hepatitis B with the goal of complete viral cure. On May 27, 2026, Precision presented new and late-breaking clinical data from the ongoing ELIMINATE-B study at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain. The data cut on May 4, 2026, was based on 38 doses administered across 16 patients in 5 cohorts. Key Findings: Liver biopsy data demonstrated a 1-log (10-fold) reduction in cccDNA-derived transcripts in one patient after only two administrations of PBGENE-HBV at 0.4 mg/kg, with less than 1% of cccDNA remaining post-treatment. Further biopsy analysis of a second patient, who received three doses at the same dose level and schedule, demonstrated that repeat administrations of PBGENE-HBV cumulatively increase the anti-cccDNA effect in the liver. Together, the biopsy data delivered the first ever clinical proof that a gene editor can directly target and eliminate cccDNA in chronic hepatitis B patients. While molecular biopsies provide clear evidence of cccDNA editing, HBV pre-genomic RNA (pgRNA) is the best blood biomarker for cccDNA elimination. pgRNA is exclusively produced from cccDNA and is the only source of new infectious virions, measured in the blood as HBV DNA. Following treatment with PBGENE-HBV, pgRNA became durably undetectable in 100% of patients who had detectable pgRNA prior to treatment. Importantly, the loss of pgRNA was ongoing for up to six months as of the data cut-off. This sustained loss of pgRNA demonstrates the durability of PBGENE-HBV’s elimination mechanism designed to directly target and eradicate cccDNA. In other important secondary serum biomarkers, substantial S-antigen declines were observed in 100% of patients treated, and durability was demonstrated in patients across all dose levels being investigated ranging from 0.2mg/kg to 0.8mg/kg. Additionally, the first patient dosed in the ELIMINATE-B trial continued to demonstrate substantial reductions more than one year after dosing. No dose-limiting toxicities have been observed in 16 patients across five cohorts. The etiology of LNP-related hypotension observed during dose escalation was identified and ameliorated through straightforward mitigation measures such as a longer infusion time and a short course of steroids at the time of infusion. Since the data update, Precision has opened new trial sites and continues enrolling additional patients, expanding cohorts 4 (0.4 mg/kg) and 5 (0.65 mg/kg), while collecting additional biopsies and blood biomarker data to further assess viral elimination. The current and future datasets are expected to inform selection of the optimal dosing schedule for Part 2 expansion. Precision continues its work with global investigators for next phase study design and expects to provide additional updates on the ELIMINATE-B trial progress by the end of 2026. PBGENE-DMD (Muscle Targeted Gene Excision Program) PBGENE-DMD is Precision's development candidate for Duchenne muscular dystrophy (DMD) designed to durably improve function for approximately 60% of patients with DMD. By employing two complementary ARCUS nucleases in a single AAV, PBGENE-DMD excises exons 45-55 of the dystrophin gene, restoring expression of a near full-length dystrophin protein. The company presented new preclinical data at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting in Boston, Massachusetts. The new data showed that treatment with PBGENE-DMD in early-juvenile mice resulted in significantly higher efficacy across key skeletal and respiratory muscles than treatment in late-juvenile mice over a comparable timeframe. This new data further supports evaluating PBGENE-DMD in younger DMD patient populations, including the 2- to 3-year-old patients, who are a key demographic of the ongoing Phase 1/2 FUNCTION-DMD trial evaluating PBGENE-DMD in boys ages 2 to 7. Precision continues to advance the Phase 1/2 FUNCTION-DMD clinical trial, with two clinical trial sites now active: Arkansas Children's Hospital in Little Rock and Washington University School of Medicine in St. Louis, both recognized centers of excellence for DMD care. The study is actively recruiting patients with initial safety data expected for year-end 2026. Partnered In Vivo Programs: iECURE-OTC (Gene Insertion Program) Led by iECURE, Inc. (iECURE) ECUR-506 is an ARCUS-mediated in vivo targeted gene insertion program currently in a first-in-human trial (OTC-HOPE) evaluating ECUR-506 as a potential treatment for neonatal-onset ornithine transcarbamylase (OTC) deficiency. iECURE previously announced alignment with the FDA on key study elements that could support a potential Biologics License Application (BLA). The OTC-HOPE study is ongoing in the U.K., the U.S., Australia, and Spain. iECURE presented clinical data at the ASGCT Annual Meeting in May, including preliminary data from study participants in the first three dose cohorts (n=7) of the ongoing OTC-HOPE study, and demonstrated that 71% of participants experienced no hyperammonemic crises following ECUR-506 administration. In addition, iECURE presented a poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting in May 2026 featuring one-year post-treatment data from the first infant dosed in the study who achieved a complete clinical response as defined by study protocol. Partnered Ex Vivo Programs : Azer-cel (Azercabtagene Zapreleucel Allogeneic CAR T Treatment for Cancer) Imugene Limited continues development of azer-cel in diffuse large B-cell lymphoma and has received written guidance from the FDA regarding the registrational pathway for azer-cel. The guidance provided clear alignment with the FDA across key elements required to support advancement into a pivotal study, including dosing regimen, patient population, endpoints, and manufacturing readiness. Azer-cel data presented at the 2026 American Society of Clinical Oncology Annual Meeting in May 2026 demonstrated that among 24 patients evaluable for response following their first disease assessment at Day 28, response rates ranging from 50%-100% were observed across all six cancer subtypes. Azer-cel (Azercabtagene Zapreleucel Allogeneic CAR T Treatment for Multiple Sclerosis) Separately, azer-cel is being evaluated by TG Therapeutics, Inc. (Nasdaq: TGTX) in a Phase 1 trial in progressive multiple sclerosis. In April 2026, Precision received a clinical milestone cash payment under its license agreement with TG Therapeutics. The payment of $7.5 million was inclusive of $5.25 million cash and $2.25 million for the purchase of shares of Precision common stock by TG Therapeutics. Corporate Developments: Precision announced changes to its senior leadership team to support advancement of its programs through the next set of clinical milestones. On August 1, 2026, Alex Kelly, formerly Chief Financial Officer, was promoted to the newly created role of Chief Operating Officer where he will oversee all key customer-facing functions. Naresh Tanna, formerly Vice President of Investor Relations and Chief of Staff to the CEO, was promoted to Chief Financial Officer where he will oversee corporate finance, reporting and investor relations. In addition, Cassie Gorsuch, PhD, Chief Scientific Officer, now leads all research functions, including clinical stage translational sciences and next generation programs. Precision announced its addition to the Russell 2000® Index, effective at the close of U.S. equity markets on June 26, 2026, according to the final list of additions published by FTSE Russell expanding market visibility with institutional investors. Quarter Ended June 30, 2026 Financial Results: Cash, Cash Equivalents, and Restricted Cash: As of June 30, 2026, Precision had approximately $112.4 million in cash, cash equivalents, and restricted cash. The Company expects that existing cash and cash equivalents, continued fiscal and operating discipline, and availability of Precision’s at-the-market facility will fund the Company’s cash runway through 2028. Based on its expected cash runway, Precision believes it is sufficiently capitalized to achieve PBGENE-HBV and PBGENE-DMD data milestones through 2028. Revenues: As expected, no revenue was reported for the quarter ended June 30, 2026 compared to less than $0.1 million for the quarter ended June 30, 2025. Revenue from the prior period was recognized from the Novartis Agreement. Research and Development Expenses: Research and development expenses were $12.4 million for the quarter ended June 30, 2026, as compared to $12.8 million for the quarter ended June 30, 2025. The decrease of $0.4 million was primarily due to decreases in platform development and research expenses, partially offset by increases in PBGENE-DMD and PBGENE-HBV clinical program costs as the programs continue to advance globally. General and Administrative Expenses: General and administrative expenses were $6.8 million for the quarter ended June 30, 2026, as compared to $9.1 million for the quarter ended June 30, 2025. The decrease of $2.3 million was primarily a result of operational discipline and lower employee-related costs. Other Expense : Total other expense was $13.5 million for the quarter ended June 30, 2026, compared to $1.6 million total other expense for the quarter ended June 30, 2025. The increase of $11.9 million was primarily due to non-cash fair value adjustments, primarily from the loss on change in fair value of the warrant liability. Precision’s stock price appreciation as compared to the prior measurement period resulted in an increase in warrant liability and a corresponding non-cash loss. This loss does not impact operating loss or cash runway. Net Loss: Net loss was $32.7 million, or $(1.26) per share (basic and diluted), for the quarter ended June 30, 2026. Net loss was $23.5 million, or $(2.13) per share (basic and diluted), for the quarter ended June 30, 2025. This increase in net loss compared to the prior period is primarily driven by the non-cash loss from the warrant liability and does not affect loss from operations or cash runway. About Chronic Hepatitis B Chronic hepatitis B virus causes inflammation and damage to the liver, leading to chronic infection and increased risk of death from liver cancer or cirrhosis. There is no cure for chronic hepatitis B, and current treatments rarely result in a functional cure, primarily due to persistence of viral DNA in the liver. In patients with chronic hepatitis B, genetic material of the virus is converted within infected liver cells into cccDNA that acts as the only template to make new infectious viral particles. Hepatitis B virus also inserts fragments of its DNA into the human genome of infected liver cells. These integrated fragments are viral replication incompetent and cannot produce new infectious virus. Both cccDNA and integrated HBV DNA produce the viral protein, hepatitis B surface antigen (HBsAg), which is secreted in the blood. Historically, the focus for drug development and regulatory approval of drugs for chronic hepatitis B has relied on the temporary suppression of HBsAg. Achieving undetectable HBsAg may lead to a functional cure if there is no rebound in HBV DNA or HBsAg after drug treatment has been discontinued for at least six months, but this is achieved in less than three out of 100 patients treated with the current standard of care. Since cccDNA is the only source of infectious particles (HBV DNA), elimination of cccDNA results in a viral cure of chronic hepatitis B. Sustained loss of HBV DNA alone as a result of cccDNA elimination is an approvable endpoint for the FDA and highly relevant for PBGENE-HBV. About PBGENE-HBV, A Viral Elimination Program PBGENE-HBV is Precision’s wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for chronic Hepatitis B infection. PBGENE-HBV is the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate the root cause of chronic hepatitis B, cccDNA, while inactivating integrated HBV DNA. Elimination of cccDNA results in HBV viral cure as cccDNA is the only source of infectious replication (HBV DNA). The ELIMINATE-B trial is investigating PBGENE-HBV at multiple dose levels across a number of administrations per dose level in patients with chronic Hepatitis B. PBGENE-HBV has been granted Fast Track designation by the FDA. The FDA has previously provided guidance that sustained loss of HBV DNA is an approvable endpoint for chronic hepatitis B. Further details on the trial can be found on Precision’s website and on clinicaltrials.gov identifier NCT06680232. About PBGENE-DMD, A Muscle-Targeted Excision Program PBGENE-DMD is Precision’s development program for the treatment of DMD. DMD is a genetic disease caused by mutations in the dystrophin gene that prevent production of the dystrophin protein and affects approximately 15,000 patients in the U.S. alone. There are currently no approved therapies that can drive durable and significant functional improvements over time. PBGENE-DMD is designed to improve function for approximately 60% of patients afflicted with DMD by employing two complementary ARCUS nucleases delivered in a single AAV to excise exons 45-55 of the dystrophin gene. Compared with DMD, deletion of exons 45-55 is often associated with a milder prognosis for patients. The aim of this approach is to restore a near full-length functional dystrophin protein within the body that more closely resembles normal dystrophin as opposed to synthetic, truncated microdystrophin approaches with minimal functional benefit. The Phase 1/2 FUNCTION-DMD study is expected to enroll ambulatory DMD patients with mutations between exons 45 and 55. The clinical trial will employ an appropriate immune modulation regimen and safety monitoring program to treat ambulatory patients at world class specialized DMD clinical sites. PBGENE-DMD was granted Orphan Drug Designation by the FDA in July 2025. The PBGENE-DMD program is eligible for a Priority Review Voucher (PRV) via the Rare Pediatric Disease Priority Review Voucher (PRV) program, which was signed into law on February 3, 2026, as part of the Consolidated Appropriations Act of 2026. PBGENE-DMD received Fast Track designation from the FDA in February 2026. Further details on the trial can be found on Precision’s website and on clinicaltrials.gov identifier NCT07429240. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of clinical stage in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit . The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination (removing a genome e.g. viral DNA such as in the Company’s PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company’s PBGENE-DMD program) and gene insertion (inserting DNA into gene to cause expression/add function). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the key advantages of ARCUS and its key capabilities and differentiating characteristics; expectations about operational initiatives, strategies, further development, or timing of additional updates or data releases of PBGENE-HBV and PBGENE-DMD, timing and progress of site activation, patient recruitment, and enrollment for the FUNCTION-DMD and ELIMINATE-B clinical trials; expected timing of program or clinical updates or progress for the FUNCTION-DMD and ELIMINATE-B clinical trials by the end of 2026, including an expectation of initial safety data in the FUNCTION-DMD study; administrations of PBGENE-HBV across cohorts and the evaluation on the impact of escalating dose levels and dosing intervals; the goal of complete viral cure in PBGENE-HBV, the expectation of current and future ELIMINATE-B dataset to inform selection of the optimal dosing schedule for Part 2 expansion; the design of PBGENE-HBV to eliminate cccDNA and inactivate integrated HBV DNA with high specificity, potentially leading to cure; the suitability of PBGENE-HBV for the treatment of hepatitis B and the targeting of the root cause of the disease; the adequacy of mitigation measures in LNP-related hypotension observed during dose escalation; the design of PBGENE-DMD to durably improve function for approximately 60% of patients with DMD; translation of results in preclinical studies of ARCUS nucleases to clinical studies in humans; the preclinical and clinical development and demonstrated, potential and expected safety, efficacy, durability, and benefit of PBGENE-HBV and PBGENE-DMD, as well as our other product candidates and those being developed by partners; expectations of continued azer-cel development by licensees or partners; and the sufficiency of our expected cash runway to extend through 2028 to enable PBGENE-HBV and PBGENE-DMD data milestones. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “belief”, “believe,” “contemplate,” “could,” “design,” “designed,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “strive,” “suggest,” “target,” “will,” “would,” or the negative thereof and similar words and expressions. Forward-looking statements are based on management’s current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators’ or other licensees’ ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators’ or other licensees’ development of product candidates; our or our collaborators’ or other licensees’ ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators’ and other licen Contacts Investor and Media Contact: Naresh Tanna Chief Financial Officer naresh.tanna@precisionbiosciences.com Read full story here